These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6826129)

  • 1. [Do we need new drugs?].
    Deck K
    Fortschr Med; 1983 Jan; 101(3):49-50, 87. PubMed ID: 6826129
    [No Abstract]   [Full Text] [Related]  

  • 2. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 3. [Must drugs be expensive?].
    Dippner H
    Zahnarztl Mitt; 1980 May; 70(10):649. PubMed ID: 6930794
    [No Abstract]   [Full Text] [Related]  

  • 4. [The negative list--a false step in the right direction].
    Rempen E
    Fortschr Med; 1982 Dec; 100(45):2093-5. PubMed ID: 7173793
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bitter pills for insurance patients].
    Lüth P
    Fortschr Med; 1983 Oct; 101(37):1643-4. PubMed ID: 6642374
    [No Abstract]   [Full Text] [Related]  

  • 6. [About medicines. Production, advertising, abuse and side effects of our drugs].
    Spegg H
    Dtsch Krankenpflegez; 1974 Jun; 27(6):290-7. PubMed ID: 4495221
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 8. [In support of drug transparency].
    Platzer E
    MMW Munch Med Wochenschr; 1979 May; 121(19):suppl 25-6. PubMed ID: 112383
    [No Abstract]   [Full Text] [Related]  

  • 9. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Technical discussions at the 20th Panamerican Health Conference. Repercussions of the cost of drugs on the cost of health: national and international problems].
    Bol Oficina Sanit Panam; 1979 Dec; 87(6):471-93. PubMed ID: 161718
    [No Abstract]   [Full Text] [Related]  

  • 11. [An end to scurrilous recommendations on the new regulation. What is still allowed on the insurance form?].
    Schmidt K
    MMW Fortschr Med; 2004 Apr; 146(15):60-2. PubMed ID: 15373023
    [No Abstract]   [Full Text] [Related]  

  • 12. The older adult and drug therapy: Part two. Thirteen drugs and what they cost.
    Geriatr Nurs; 1982; 3(1):48-9. PubMed ID: 6916681
    [No Abstract]   [Full Text] [Related]  

  • 13. [The carrot and the stick for physicians and pharmacists. A questionable model for the Bavaria contract on reducing the price of drug therapy].
    Girstenbrey W
    Fortschr Med; 1984 Jun; 102(24):72-3. PubMed ID: 6469183
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of essential drugs and primary health care. What are the important next steps?
    Lohse AW; Vaughan JP
    J Trop Med Hyg; 1983 Aug; 86(4):131-7. PubMed ID: 6668633
    [No Abstract]   [Full Text] [Related]  

  • 15. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalized medications.
    Koo V
    CMAJ; 2001 Nov; 165(11):1467-8. PubMed ID: 11762567
    [No Abstract]   [Full Text] [Related]  

  • 17. [Liability for drug-related damage by the pharmaceutical industry and the physician].
    Dahse G
    Beitr Gerichtl Med; 1982; 40():21-2. PubMed ID: 7165639
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical industry overview: optimal drug therapy.
    Blake P
    Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.
    Trusheim MR; Berndt ER; Douglas FL
    Nat Rev Drug Discov; 2007 Apr; 6(4):287-93. PubMed ID: 17380152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine: challenges in assessing and capturing value in the commercial environment.
    Ferrara J
    Expert Rev Mol Diagn; 2006 Mar; 6(2):129-31. PubMed ID: 16512770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.